Prosecution Insights
Last updated: May 29, 2026

Creative Medical Technologies Inc.

18 pending office actions • 10 art units • 17 examiners • 0 of 18 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

18
Total Pending OAs
15
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

14
Overdue
1
Due this week
1
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (14)Due ≤ 7 days (1)Due ≤ 30 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
15
Medium (83%)
1
Easy (6%)
2
Unknown (11%)

Rejection Statute Mix

BucketCases
§103 only14 (78%)
§102 only1 (6%)
§112 only1 (6%)
No statute on record2 (11%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

18
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

180 h
Manual time on pending OAs
36 h
Time saved (low, 20%)
63 h
Time saved (mid, 35%)
1.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KASAYAN, KATRIEL BARCELLANO 2 100.0% +0.0%
MOORE, JOHN DAVID 1 70.5% +18.1%
VIJAYARAGHAVAN, JAGAMYA NMN 1 67.7% +39.0%
ABEYRATNE-PERERA, HASHANTHI KOMITIGE 1
CANDELARIA, JULIANA IRENE 1
CRAIG, KAILA ANGELIQUE 1 32.8% +26.7%
KUMAR, SRILAKSHMI K 1 55.4% +15.6%
SMITH, ADAM MICHAEL 1
ALDARONDO, DASIA ALI 1 0.0% +0.0%
KIM, TAEYOON 1 51.5% +51.4%

Quick Wins (2)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18331048 GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED ENDOTHELIAL PROGENITOR CELLS KASAYAN, KATRIEL BARCELLANO 50d overdue
18311625 CYTOKINE PRIMED REGENERATIVE CELLS FOR TREATMENT OF OVARIAN FAILURE KASAYAN, KATRIEL BARCELLANO 46d overdue

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18311474 STIMULATION OF OVARIAN FUNCTION SUBSEQUENT TO CHEMOTHERAPY AND/OR RADIATION THERAPY USING NATURAL KILLER CELLS ALDARONDO, DASIA ALI 42d overdue

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18300210 ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL KIM, TAEYOON 161d overdue
18366527 PROPHYLAXIS AND TREATMENT OF ORTHOPOX VIRUSES USING REGENERATIVE CELLS AND PRODUCTS THEREOF MOORE, JOHN DAVID 113d overdue
18366539 PREVENTION OF SPACE TRAVEL ASSOCIATED BONE DENSITY LOSS BY REGENERATIVE CELL POPULATIONS VIJAYARAGHAVAN, JAGAMYA NMN 103d overdue
18311445 CYTOKINE BASED ASSESSMENT OF RECIPIENT ABILITY TO RESPOND TO STEM CELL THERAPY FOR CARTILAGE REGENERATION KUMAR, SRILAKSHMI K 9d overdue
18315364 EXOSOME BASED ASSAYS FOR DETERMINING CANDIDATES FOR OSTEOARTHRITIS STEM CELL THERAPY CRAIG, KAILA ANGELIQUE

Top Art Units

Art UnitApps
1638 3
1634 3
1647 3
1633 2
1632 2
1618 1
1796 1
1631 1
1644 1
1642 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18366527 PROPHYLAXIS AND TREATMENT OF ORTHOPOX VIRUSES USING REGENERATIVE CELLS AND PRODUCTS THEREOF MOORE, JOHN DAVID 1638 §103 Non-Final OA 113d overdue Pending Aug 07, 2023
18366539 PREVENTION OF SPACE TRAVEL ASSOCIATED BONE DENSITY LOSS BY REGENERATIVE CELL POPULATIONS VIJAYARAGHAVAN, JAGAMYA NMN 1633 §103 Non-Final OA 103d overdue Pending Aug 07, 2023
18358490 POTENTIATION OF BONE MARROW CELL ACTIVITY BY COADMINISTRATION WITH OXYTOCIN ABEYRATNE-PERERA, HASHANTHI KOMITIGE 1632 §103 Non-Final OA 71d overdue Pending Jul 25, 2023
18348292 TREATMENT OF LIMB ISCHEMIA BY BONE MARROW STEM CELLS AND MODIFICATION OF DISEASED MICROENVIRONMENT CANDELARIA, JULIANA IRENE 1634 Other Non-Final OA 80d overdue Pending Jul 06, 2023
18331048 GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED ENDOTHELIAL PROGENITOR CELLS KASAYAN, KATRIEL BARCELLANO 1634 §103 Non-Final OA 50d overdue Pending Jun 07, 2023
18315364 EXOSOME BASED ASSAYS FOR DETERMINING CANDIDATES FOR OSTEOARTHRITIS STEM CELL THERAPY CRAIG, KAILA ANGELIQUE 1618 §103 Final Rejection Pending May 10, 2023
18311445 CYTOKINE BASED ASSESSMENT OF RECIPIENT ABILITY TO RESPOND TO STEM CELL THERAPY FOR CARTILAGE REGENERATION KUMAR, SRILAKSHMI K 1796 §103 Non-Final OA 9d overdue Pending May 03, 2023
18311625 CYTOKINE PRIMED REGENERATIVE CELLS FOR TREATMENT OF OVARIAN FAILURE KASAYAN, KATRIEL BARCELLANO 1634 §103 Non-Final OA 46d overdue Pending May 03, 2023
18311464 PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION SMITH, ADAM MICHAEL 1638 §103 Non-Final OA 83d Pending May 03, 2023
18311474 STIMULATION OF OVARIAN FUNCTION SUBSEQUENT TO CHEMOTHERAPY AND/OR RADIATION THERAPY USING NATURAL KILLER CELLS ALDARONDO, DASIA ALI 1647 §103 Non-Final OA 42d overdue Pending May 03, 2023
18300210 ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL KIM, TAEYOON 1631 §103 Non-Final OA 161d overdue Pending Apr 13, 2023
18183900 THERAPEUTIC REGENERATIVE CELLS REGLAS, GILLIAN CHELSEA 1632 §103 Non-Final OA 73d overdue Pending Mar 14, 2023
18173052 METHODS FOR QUANTIFYING POTENCY OF REGENERATIVE IMMUNOTHERAPIES YOUTCHOM PENDIE, EMMANUEL LED 1647 §103 Non-Final OA 17d overdue Pending Feb 22, 2023
18082841 CHIMERIC ANTIGEN RECEPTOR REGENERATIVE GAMMA DELTA T CELLS BELYAVSKYI, MICHAIL A 1644 Other Final Rejection 21d Pending Dec 16, 2022
18082857 REGENERATIVE CAR-T CELLS RAHMAN, MASUDUR 1633 §102 Non-Final OA 89d overdue Pending Dec 16, 2022
17931868 SUPPRESSION OF DIABETES USING EXOSOMES FROM STEM CELL PROGRAMMED MYELOID CELLS BUNNER, BRIDGET E 1647 §112 Final Rejection 5d overdue Pending Sep 13, 2022
17865881 Therapeutic Monocytic Lineage Cells JOHNSON, ALLISON MARIE 1638 §103 Non-Final OA 19d overdue Pending Jul 15, 2022
17585356 TREATMENT OF KIDNEY FAILURE USING EX VIVO REPROGRAMMED IMMUNE CELLS STONEBRAKER, ALYSSA RAE 1642 §103 Non-Final OA 7d Pending Jan 26, 2022

Managing Creative Medical Technologies Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month